All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

During past decades, health economic evaluations have become increasingly important to the evaluation of new health technologies. Many countries have addressed common issues related to the process of health technology assessment (HTA) while elaborating guidelines regarding the process to evaluate such technologies, and the evidence-based decision making has been adopted by health systems around the world and by academia\[[@pntd.0003527.ref001],[@pntd.0003527.ref002]\] Nevertheless, health technology assessment and specifically health economic evaluation are still scarce for the so-called neglected tropical diseases (NTD). This is an alarming fact, considering that NTDs present higher burden of disease than some non-communicable diseases\[[@pntd.0003527.ref003],[@pntd.0003527.ref004]\], and mainly affect the poorest regions and populations of the globe\[[@pntd.0003527.ref005]--[@pntd.0003527.ref007]\], to the point of being classified as diseases of poverty. For that reason, supporting an efficient resource allocation process with health economic evidence is imperative, as poor populations are vulnerable to a wide spectrum of diseases, and are assisted by budget restricted health systems.

Visceral leishmaniasis (VL), one of the NTDs, is a life threatening infectious disease affecting around 500,000 and killing 50,000 individuals a year\[[@pntd.0003527.ref008]--[@pntd.0003527.ref010]\]. India, Brazil, Sudan, Nepal, Ethiopia and Bangladesh concentrate 90% of cases\[[@pntd.0003527.ref008]\]. Malaria is currently the sole tropical infectious disease responsible for more deaths than VL. Notwithstanding the public health importance of VL, the availability of new treatments is very restricted and the narrow development pipeline of new strategies to manage this disease (control, diagnostic, treatment) highlights the importance of evaluating the technologies already on the market and of forecasting the scenarios of new technology incorporation.

The objective of this review was to identify, describe and classify the scientific production on economic evaluations of VL interventions. We adopted a similar methodology to the study by Walker and Fox-Rushby\[[@pntd.0003527.ref011]\] for communicable diseases in developing countries.

Methods {#sec006}
=======

Search Strategy {#sec007}
---------------

A web search combining free text and MeSH terms related to the economic evaluation of Visceral Leishmaniasis was used in Web of Science, Scopus, Medline via the Pubmed and Lilacs ([Table 1](#pntd.0003527.t001){ref-type="table"}), without language or publication date restriction. The search was carried out during January of 2013. A manual search of references lists of articles previously identified by the authors was also included, although the web search was able to cover the entire reference list identified in articles. The aim of the search strategy was to identify economic evaluation studies. An economic evaluation encompasses the study of costs and outcomes related to the use of a technology. The simplest form of evaluation is a cost-minimization analysis, which consists of comparing only the costs related to the use of a new technology compared to an alternative called the compactor. This approach assumes that there is no difference in the outcomes, so the goal is to identify the least costly option. Another type of economic evaluation is called cost-effectiveness analysis in which a comparison of the various technology options is undertaken, and the costs are measured in monetary units, and then aggregated, and outcomes are expressed in natural (non-monetary) units, which are called effectiveness of the technology. A similar kind of economic evaluation consists of comparing various options, in which costs are also measured in monetary units and outcomes are measured in a utility units, usually quality-adjusted life years or disability-adjusted life years. One can also conduct an evaluation of the financial impact of the introduction of a technology on the budgets of a government or agency.

10.1371/journal.pntd.0003527.t001

###### Search strategy.

![](pntd.0003527.t001){#pntd.0003527.t001g}

  BASE             SEARCH KEY                                                                                                                                                                     RESULTS   SELECTED
  ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------- ----------
  Web of Science   TS = (\"cost-effectiveness\" OR \"cost-utility\" OR \"cost-minimization\" OR \"cost-benefit\" OR \"economic impact\") AND TI = \"visceral leishmaniasis\"                      18        16
  PUBMED           ((\"cost-effectiveness\" OR \"cost-utility\" OR \"cost-minimization\" OR \"cost-benefit\" OR \"economic impact\"\[Title/Abstract\])) AND \"visceral leishmaniasis\"\[Title\]   22        18
  SCOPUS           TITLE-ABS-KEY(\"cost-effectiveness\" OR \"cost-utility\" OR \"cost-minimization\" OR \"cost-benefit\" OR \"economic impact\") AND TITLE(\"visceral leishmaniasis\")            66        14
  LILACS           "costo efectividad" \[palavras\] and "leishmaniasis" \[palavras\]                                                                                                              1         1

Inclusion Criteria {#sec008}
------------------

The study included all articles that explicitly proposed to conduct economic evaluations on visceral leishmaniasis in the title, abstract or objectives. Articles written in English, Portuguese, Spanish or French were considered suitable for inclusion.

Exclusion Criteria {#sec009}
------------------

After analyses by two researchers, studies that did not describe economic evaluations, or did not analyze interventions to control visceral leishmaniasis, editorials, reviews or methodological articles were excluded.

Data Analysis {#sec010}
-------------

All articles selected were evaluated and data were organized on a standardized spreadsheet prepared to collect relevant information on articles, definitions, methods and results. Articles were evaluated considering the country of origin; the payers perspective; study design; technologies evaluated ([table 2](#pntd.0003527.t002){ref-type="table"}); comparator; cost-effectiveness threshold adoption; outcomes measures.

10.1371/journal.pntd.0003527.t002

###### Technologies evaluated.

![](pntd.0003527.t002){#pntd.0003527.t002g}

  ID   Transmission Control   Vaccine   Diagnostic Tools   Drugs                                           
  ---- ---------------------- --------- ------------------ ------- ---- ---- ---- ---- ---- ---- ---- ---- ----
  A    \*                                                               \*        \*   \*             \*   
  B    \*                               \*                         \*        \*   \*                       
  C                                                                               \*                       
  D                                                                \*        \*   \*                       
  E    \*                                                                                                  
  F                                                                               \*                       
  G                                                        \*                                              
  H                                                                               \*   \*        \*   \*   \*
  I                                                                                    \*                  
  J                                                                                              \*   \*   \*
  K                                                                               \*                       
  L                                                                     \*                                 
  M                                                                               \*        \*             
  N                                                                               \*   \*        \*   \*   

Protocol registration: The current systematic review protocol was registered on the International prospective registry of systematic reviews---PROSPERO and received registration id: 2014:CRD42014007534

Results {#sec011}
=======

Search Strategy {#sec012}
---------------

The initial search retrieved 107 articles whose abstracts were screened for inclusion criteria, leading to 49 abstracts that were also screened for duplicates. This strategy generated a list of 21 articles that were evaluated according to defined exclusion criteria by at least two researchers, thus resulting in 14 articles\[[@pntd.0003527.ref012]--[@pntd.0003527.ref025]\] included for description and analysis, [Fig 1](#pntd.0003527.g001){ref-type="fig"}.

![Selection of articles.](pntd.0003527.g001){#pntd.0003527.g001}

Characteristics of Studies {#sec013}
--------------------------

The analysis regarding country of origin of the 14 studies selected, [Fig 2](#pntd.0003527.g002){ref-type="fig"}, showed a concentration of studies in the same five countries responsible for 90% of LV cases. We should highlight that India concentrates almost 7(50%) of studies and that, regardless of all its specificities, VL in the Americas accounts for only 1(7%) article published in 1996.

![Geographic distribution of studies.](pntd.0003527.g002){#pntd.0003527.g002}

All articles were published from 1996 to 2012 based on data from 1988 to 2011, [Fig 3](#pntd.0003527.g003){ref-type="fig"}.

![Time distribution of studies.](pntd.0003527.g003){#pntd.0003527.g003}

Articles were classified by type of economic study, whether cost-effectiveness, cost-benefit, cost-minimization or cost-of-illness analysis. Considering this classification, cost-effectiveness studies were the most frequent, representing 7(50%) of total studies [Fig 4](#pntd.0003527.g004){ref-type="fig"}. Technologies assessed are presented in [Table 2](#pntd.0003527.t002){ref-type="table"}, and as expected they mainly refer to drugs, albeit the small number of studies evaluating the most recent drugs available. This pattern was also present in the evaluation of diagnostic methods with only two articles assessing the new rapid test for VL diagnosis. It is also important to point out that technologies aiming at the transmission of VL are very under assessed in the literature reviewed, capturing only one cost-of-illness article that evaluated the use of insecticides, and one cost-effectiveness analysis of vaccines that was only possible by the simulation of scenarios regarding the hypothetical intervention. In relation to methods applied, studies were classified in the following categories: clinical-trials (piggy-back)\[[@pntd.0003527.ref026]\], pharmacoeconomic modelling, and others (i.e.: surveys). It is important to point out that 8(57%) of economic evaluations of VL were trial based [Fig 5](#pntd.0003527.g005){ref-type="fig"}.

![Studies by type of economic evaluation.](pntd.0003527.g004){#pntd.0003527.g004}

![Economic evaluations by method used.](pntd.0003527.g005){#pntd.0003527.g005}

Among the 13 (93%) articles that declared the perspective of the analysis, 5 (38%) adopted the societal perspective and 8 (62%) performed economical evaluation according to the payers' perspective, 2(25%) of which with patients or their families considered as payers, and 6 (75%) to the health system. Outcomes were presented as averted Years of Life Lost, 1 (7%); patients cured, 1 (7%); monetary units, 2 (14%); averted deaths, 3 (21%); averted disability-adjusted life years (DALY), 3 (21%); and "treatments", 4 (28%). Most studies presented monetary units as US\$, 13 (93%); and one article presented Nepalese Rupies NR, 1 (7%). Cost-effectiveness threshold was presented by 4 (57%) of the CE studies; three (75%) of these studies adopted the WHO choice criteria of 1 to 3 x GDP per capita/ averted DALY\[[@pntd.0003527.ref027]\]; and 1 (25%) study adopted a threshold of U\$ 25/ averted DALY. It is important to note that only one study presented a CE acceptability curve. The only three (43%) CE studies that applied discount rates to cost or outcomes chose a rate of 3% a year.

Sensitivity analyses were performed on 7 (50%) studies, 72% of which used multivariate sensitivity analyses. Modelling was used by 29% of all selected studies, with three (75%) based on decision trees and one (25%) based on Markov chain models.

[Table 3](#pntd.0003527.t003){ref-type="table"} presents the outcomes, and inflation adjusted costs for the most cost-effective (or cost-saving) intervention of each study. The inflation adjusted costs were also purchasing power parity converted considering the 2013 PPP conversion rate\[[@pntd.0003527.ref028]\].

10.1371/journal.pntd.0003527.t003

###### Costs and outcomes for the most cost-effective (cost saving) interventions.

![](pntd.0003527.t003){#pntd.0003527.t003g}

  Study ID   Costs I\$   Outcome measure
  ---------- ----------- -----------------
  A          0.014       1 I\$
  J          8.4024      Averted YLL
  E          21.9891     Household
  F          238.9442    Averted DALY
  B          267.6986    Averted DALY
  H          382.3464    Averted death
  C          391.1861    Averted death
  L          603.0658    Treated patient
  K          611.7021    Treated patient
  N          1733.6182   Averted death
  M          1887.9591   Treated patient
  D          2316.0403   Averted death
  I          2834.4347   VL case
  G          2861.9950   Averted DALY

All articles were evaluated following the Consolidated Health Economic evaluation reporting standards (CHEERS) statement\[[@pntd.0003527.ref029]\], and the result is presented as supplementary material. It's interesting to note that the majority of studies lacked information on time horizon 12(85,7%); measurement of effectiveness 12(85,7%); measurement and valuation of preference based outcomes 13(92,9%); characterizing uncertainty 12(85,7%); characterizing heterogeneity 12(85,7%); and conflicts of interest 12(85,7%).

Discussion {#sec014}
==========

Despite the importance of VL as a public health problem\[[@pntd.0003527.ref030]\], expressed by its estimated world burden of disease of 2,357,000\[[@pntd.0003527.ref031]\] disability-adjusted life years, the search strategy was not able to identify a large number of articles on VL health economic evaluation. This fact may be explained in part by the scarce development of VL control strategies during past years, but it may also reflect the unawareness of poverty related diseases.

The analysis of the articles selected showed a large concentration of studies carried out in the Asian continent, especially in India, which is the country with the highest VL incidence\[[@pntd.0003527.ref032]\]. Due to such concentration, the literature has not dealt with some local VL characteristics such as: different Leishmania species causing VL; different vector species, specific site related hosts; heterogeneous drug resistance profiles; and local socio-demographic characteristics. As a complex vector transmitted disease, VL control is not a straightforward action. It relies on interventions to control transmission (including vaccines), diagnosis, and treatment \[[@pntd.0003527.ref008],[@pntd.0003527.ref010]\]. By disregarding these characteristics, most of the studies did not consider the assessment of combined interventions, what may be a weakness for the economic evaluation of transmissible diseases.

Although the scientific literature has previously emphasized the advantages of using dynamic models while conducting cost-effectiveness studies on infectious diseases\[[@pntd.0003527.ref026],[@pntd.0003527.ref033]\], none of the studies analyzed was based on dynamic transmission models. This fact may reflect an excessive simplification of VL disease history, by not including the importance of interactions of hosts and vectors, or by not dealing with the development of drug resistance.

When presenting cost-effectiveness acceptability thresholds, the authors decided to follow WHO recommendations of less than 3 x GDP per QALY or averted DALY for cost-effective interventions and less than 1 x GDP per QALY or averted DALY for very cost-effective interventions. Nevertheless, it is very important to mention that these thresholds are not able to address income inequality, which is particularly high in endemic countries of visceral leishmaniasis.

Despite the representation of endemic countries on the investigation teams, the majority of articles were produced with foreign cooperation, suggesting that the capillarity of the techniques used in economic evaluations of health interventions are still a challenge for developing countries.

Conclusion {#sec015}
----------

Visceral leishmaniasis is still an important infectious disease in many countries, especially in developing ones, so its control is of great public health importance. The development of new technologies is imperative in order to properly address VL in order to control epidemics and reduce its impact on society\[[@pntd.0003527.ref034]\].

The present review has showed that health-economic studies, which are an essential part of the health technology assessment and incorporation process, were not able to overcome gaps in knowledge of strategies to deal with such a debilitating disease.

It is also important to underscore that the majority of studies accessed by this article did not consider the societal perspective to guide the evaluation; they mainly adopted the payers\' perspective, which does not necessarily express the entire dimension of the health intervention evaluated.

Transmission control was only assessed by three studies, which may reflect the difficulty of evaluating these strategies due to the interval between intervention and epidemiologic impact, or the difficulty of linking intervention and impact.

Despite the representation of endemic countries on the investigation teams, the majority of articles were produced with foreign cooperation, suggesting that the capillarity of the techniques used in economic evaluations of health interventions are still a challenge for developing countries.

Most recent treatments for VL (ex. miltefosine, and paramomycin) were evaluated only a few times, and should be evaluated in different epidemiological scenarios. Future studies should consider a longer time horizon, so that the infectious disease characteristics and peculiarities of visceral leishmaniasis could be better expressed and accounted for.
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